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Direct pharmacological targeting of the anti-apoptotic B-cell lymphoma-2 (BCL-2) family is an attractive therapeutic strategy for
treating cancer. Obatoclax is a pan-BCL-2 family inhibitor currently in clinical development. Here we show that, although
obatoclax can induce mitochondrial apoptosis dependent on BCL-2 associated x protein/BCL-2 antagonist killer (BAX/BAK)
consistent with its on-target pharmacodynamics, simultaneous silencing of both BAX and BAK did not abolish acute toxicity or
lossof clonogenicity. This is despitecomplete inhibition ofapoptosis. Obatoclax dramatically reduced viabilitywithout inducing
loss of plasma membrane integrity. This was associated with rapid processing of light chain-3 (LC3) and reduction of S6 kinase
phosphorylation, consistent with autophagy. Dramatic ultrastructural vacuolation, not typical of autophagy, was also induced.
Silencing of beclin-1 failed to prevent LC3 processing, whereas knockout of autophagy-related (Atg)7 abolished LC3 processing
but failed to prevent obatoclax-induced loss of clonogenicity or ultrastructural changes. siRNA silencing of Atg7 in BAX/BAK
knockout mouse embryonic ﬁbroblasts did not prevent obatoclax-induced loss of viability. Cells selected for obatoclax
resistance evaded apoptosis independent of changes in BCL-2 family expression and displayed reduced LC3 processing. In
summary, obatoclax exhibits BAX- and BAK-dependent and -independent mechanisms of toxicity and activation of autophagy.
Mechanisms other than autophagy and apoptosis are blocked in obatoclax resistant cells and contribute signiﬁcantly to
obatoclax’s anticancer efﬁcacy.
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The ability of cancer cells to evade apoptosis is a hallmark of
both cancer and drug resistance.
1 Activation of the intrinsic
apoptosis pathway requires mitochondrial outer membrane
permeabilization (MOMP) mediated by the pro-apoptotic
multi-domain B-cell lymphoma-2 (BCL-2) family proteins
BCL-2 associated x protein (BAX) and BCL-2 antagonist killer
(BAK).
2 This results in adenosine triphosphate (dATP)/
cytochrome c/apaf-1-dependent activation of caspase 9
leading to executioner caspase 3/7 activation and cleavage
of numerous substrates including poly ADP ribose polymer-
ase (PARP) to mediate apoptosis.
3–7 BAX and BAK are
inhibited by anti-apoptotic BCL-2 family proteins, which
include BCL-2, BCL-2 regulated gene long isoform (BCL-xl),
BCL-2 like protein 2 (BCL-w), A1 and myeloid cell leukemia-1
(MCL-1). These are in turn antagonized by a subset of pro-
apoptotic proteins harboring a single 16-amino acid alpha
helical amphipathic BCL-2 homology domain 3 (BH3).
8,9 The
pro-survival BCL-2 family proteins MCL-1 and BCL-xl have
been shown to be among the most commonly ampliﬁed
oncogenes in the cancer genome,
10 as a result the BCL-2
family of proteins represent attractive targets for therapies in
many cancers.
11 Accordingly, recently identiﬁed small mole-
cules that mimic BH3-only proteins constitute a new class of
potentially important targeted therapeutics.
12 One such small
molecule is ABT-737 (and its orally active analog ABT-263),
13
which were discovered using a nuclear magnetic resonance-
based approach to determine structure activity relationships.
ABT-737 exhibits very high-afﬁnity binding (Ki r1nM) for
BCL-2, BCL-xl and BCL-w but not MCL-1. Consequently, high
expression of MCL-1 has been observed as a mechanism of
resistance to ABT-737.
14,15
Obatoclax is a pan-BCL-2 inhibitor discovered using a
protein–protein interaction screen of natural compound
libraries
16 and in contrast to ABT-737 binds all pro-survival
BCL-2 family members (including MCL-1), although with a
much lower afﬁnity (Ki B1–5mM).
17 Obatoclax displaces
BAK/MCL-1 and BCL-2 interacting mediator of cell death
(BIM)/MCL-1 complexes
18–23 and in so doing activates
mitochondrial apoptosis. Recent reports have implicated
off-target activities of obatoclax, possibly independent of BAX
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24 These off-
target activities include autophagy,
25–28 however, the impact
of autophagy on obatoclax-induced cytotoxicity is unclear as
the pharmacodynamics have not been explored in detail.
Here, we show that obatoclax induces autophagy-related
(Atg)7 but not beclin-1-dependent autophagy in the presence
or absence of BAX and BAK, and that this activity is
suppressed in obatoclax resistant cells.
Results
Obatoclax-induced apoptosis requires BAX and
BAK. Obatoclax has previously been shown to exhibit
on-target activity, dissociating BAK from MCL-1.
18–22 We also
observed this activity in H460 non-small-cell lung cancer
(NSCLC) cells (Figure 1a). This was associated with
induction of mitochondrial apoptosis, as evidenced by
BAK conformation change and mitochondrial membrane
permeabilization associated with BAK activation, release
of second mitochondrial derived activator of caspases
(SMAC) and cleavage of PARP (Figures 1b-d). We next
examined the requirement for BAX and BAK expression for
obatoclax-induced apoptosis using H460 NSCLC cells stably
transfected with short hairpin RNAs simultaneously targeting
both BAX and BAK (H460
shBAX/BAK). Obatoclax-induced
apoptosis was signiﬁcantly reduced in H460
shBAX/BAK cells
relative to non-targeting transfected control cells (H460
shNT/NT)
as assessed by caspase 9, caspase 3 and PARP cleavage
(Figure 2a). H460
shBAX/BAK cells failed to undergo mitochondrial
apoptosis in response to staurosporine and cell permeable pro-
apoptotic peptides corresponding to the BH3 domain of
activating BH3-only protein BCL-2 interacting domain death
agonist (BID) (data not shown). BAX/BAK-dependent apoptosis
induction by obatoclax was further conﬁrmed in BAX and BAK
double-knockout mouse embryonic ﬁbroblasts (DKO MEFs)
compared with wild-type (WT) controls (Figure 2b).
Loss of BAX/BAK fails to rescue cells following
obatoclax. To further assess the requirement for BAX and
BAK in obatoclax-induced toxicity, we looked at both its
short- and long-term effects on the viability and clonogenic
survival of H460 NSCLC cells stably transfected with
shRNAs targeting BAX and BAK (H460
shBAX/BAK)), and
BAX/BAK DKO MEFs. In contrast to the requirement for
BAX and BAK in induction of apoptosis, obatoclax was very
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Figure1 Obatoclaxexhibitson-targetactivityassociatedwithmitochondrialapoptosis.(a)ObatoclaxdisruptsBAK/MCL-1complexinH460NSCLCcells.H460cellswere
incubatedwith obatoclaxfor 6, 24 and 48h, after which timetotal cell lysate was subjected to immunoprecipitation with anti BAK antibody. Immunoprecipitates were analyzed
for MCL-1 levels by SDS–PAGE. Whole-cell lysates were also probed for BAK and MCL-1 levels by SDS–PAGE. b-Actin was used as a loading control.
(b) Obatoclax induces BAK activation in H1975 NSCLC cells. H1975 cells were treated with 500nM obatoclax for 48h. Mitochondria were then isolated and incubated with
trypsin (125mg/ml) and analyzed for BAK by SDS–PAGE and immunoblotting with an antibody directed against amino acids 23–37 of BAK (BAK-NT). VDAC was used as a
mitochondrial-speciﬁc loading control. (c) Obatoclax induces mitochondrial outer membrane permeabilization in H1975 cells. H1975 cells were treated with 500 or 750nM
obatoclax for 48h. Mitochondria were then isolated and probed for SMAC levels by SDS–PAGE. VDAC was used as a mitochondrial-speciﬁc loading control. (d) Obatoclax
induces PARP cleavage in H1975 cells. H1975 cells were treated with indicated doses of obatoclax for 48h. The level of PARP cleavage was determined by SDS–PAGE.
GAPDH was used as a loading control
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Cell Death and Diseaseeffective in reducing viability in H460
shBAX/BAK versus
H460
shNT/NT control cells and in BAX/BAK DKO MEFs
versus WT controls at both 48h (Figure 2c) and 72h (data
not shown). H460
shBAX/BAK cells exhibited a dose-dependent
loss of clonogenicity not signiﬁcantly different from H460
shNT/
NT cells (Figure 2d). Similarly, no difference in the loss of
clonogenicity was observed following Obatoclax treatment in
BAX/BAK DKO versus WT MEFs (Figure 2d). Also, when the
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Figure 2 Obatoclax-induced apoptosis is dependent upon BAX/BAK, yet loss of BAX/BAK fails to rescue cells. (a) Loss of BAX and BAK inhibits obatoclax-induced apoptosis in
H460 NSCLC cells. Apoptosis is blocked in NSCLC cells deﬁcient for BAX/BAK. H460 NSCLC cells were stably transfected with shRNAs simultaneously targeting BAX and BAK
(H460
shBAX/BAK), or with two non-targeting shRNAs as control cells (H460
shNT/NT). Two clones of shBAX/BAK cellswere taken forward to examine (H460
shBAX/BAK 4C and H460
shBAX/
BAK 1B). H460
shNT/NT and H460
shBAX/BAK 4C cells were treated with 1mM obatoclax for 48h. Cell lysates were probed for PARP, caspase 9 and caspase 3 cleavage by SDS–PAGE.
GAPDH was used as a loading control. The level of BAX and BAK knockdown in both clones was assessed by SDS–PAGE (samples run in duplicate). b-Actin served as a loading
control. (b) Obatoclax-induced apoptosis is blocked in embryonic ﬁbroblasts derived from mice deﬁcient for BAX and BAK. Wild type (WT) and BAX/BAK double-knockout (DKO)
mouse embryonic ﬁbroblasts (MEFs)were treated with 500nMobatoclax for 48h and the levelof PARPand caspase 9 cleavage determined by SDS–PAGE.a-Tubulin wasused as
a loading control. (c) Loss of BAX/BAK fails to rescue cells following obatoclax. The effect of obatoclax on the viability of H460
shBAX/BAK and BAX/BAK DKO MEFs was assessed by
ViaLight viability assay (Lonza Group Ltd.). EC50 values for each cell line were; H460
shNT/NT 690nM; H460
shBAX/BAK 1B 580nM; H460
shBAX/BAK 4C 460nM; WT MEFs 54nM; DKO
MEFs 62nM. Each data point represents mean±S.D. (d) Cellswere plated at single-cell densities and treated with indicated doses of obatoclax for 24h. Medium was replaced and
cells were allowed to form colonies. Each data point represents mean±S.E. (e) Loss of BAX/BAK fails to rescue cells over the long term. Cells were seeded in 6-well plates and
drugged at indicted doses. Cells were then monitored using the INCUCYTE live cell imaging system (Essen BioScience). Cell conﬂuency was determined using calculations derived
from phase-contrast images. This data was condensed using algorithms into quantiﬁed metrics to obtain kinetic proliferation curves
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Cell Death and Diseasegrowth kinetics of DKO MEFs was assessed over 5 days
following obatoclax treatment, there was no signiﬁcant
difference relative to their WT controls (Figure 2e).
Obatoclax induces processing of light chain-3 (LC3) and
dramatic ultrastructural changes. Despite the marked
reduction in cell viability induced by obatoclax, there was
no measurable loss of plasma membrane integrity following
72h (Figure 3a) or 96h (data not shown) exposure, as deter-
mined by adenylate kinase release into surrounding culture
media relative to untreated controls. This was in contrast to
tumor necrosis receptor-related apoptosis-inducing ligand
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Figure 3 Cellfate followingobatoclaxisdetermined by additionalmechanismsotherthan apoptosis.(a) Obatoclaxfails to inducelossin plasmamembraneintegrity.(left)
H460 and H1975 NSCLC cells were treated at indicated doses of obatoclax for 72h. H1975 cells were also treated with 20ng/ml TNF-receptor-related apoptosis-inducing
ligand(TRAIL).ViabilityofcellswasassessedbyViaLightviabilityassay(LonzaGroupLtd.).Dataareexpressedasmean±S.D.(right)H460andH1975cellsweretreatedas
for ViaLight, however, this time toxicity of cells was assessed by ToxiLight cytotoxicity assay (Lonza Group Ltd.). Data are expressed as mean±S.D. (b) Inhibition of
obatoclax-induced apoptosis by ZVAD.fmk fails to rescue cells. (left) H1975 cells were treated with 10mM pan caspase inhibitor ZVAD.fmk for 30min before treatment with
indicateddoses of obatoclax for 48h. Viability of cells was assessed by ViaLight viability assay. Data are expressed as mean±S.D. (right). The effect of ZVAD on obatoclax-
induced PARP cleavage was assessed by SDS–PAGE. GAPDH was used as a loading control. (c) Obatoclax induces signiﬁcant processing of LC3. (left) H460 and H1975
cells were treated with 500nM obatoclax for 48h and the level of LC3 processing assessed by SDS–PAGE. (right) Quantiﬁcation of the level of LC3 processing following
obatoclaxwas achievedby densitometry analysisusingImageJ.Dataare expressedasmean±S.D.(d) Obatoclax-inducedLC3processingisindependentof BAX andBAK.
(left)H460
shBAX/BAK 4Ccellsweretreatedwith1mMobatoclaxfor48handthelevelofLC3processingassessedbySDS–PAGE.GAPDHwasusedasaloadingcontrol.(right)
Wild type and BAX/BAK DKO MEFs were treated with 500nM obatoclax for 48h and the level of LC3 processing assessed by SDS–PAGE. a-Tubulin served as a loading
control.(e)Obatoclaxinducesde-phosphorylationof S6kinase.H460andH1975cellsweretreatedwith 500nMobatoclaxfor 48h andthelevel ofS6kinasephosphorylation
determined by SDS–PAGE and immunoblotting with a phospho-S6 kinase antibody that detects phosphorylation of thr389. GAPDH was used as a loading control
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Cell Death and Disease(TRAIL). Furthermore, the pan-caspase inhibitor ZVAD.fmk
failed to prevent loss of viability following obatoclax
treatment, although it blocked obatoclax-induced PARP
cleavage (Figure 3b). Together these ﬁndings suggested
that cell fate following treatment with obatoclax is determined
by additional mechanisms other than apoptosis.
Autophagy is a catabolic process involving dynamic
re-arrangement of membranes and formation of autophago-
somes and autolysosomes. Light chain 3 (LC3, mammalian
ortholog of yeast Atg8) is widely used as a reporter of
autophagosome formation. During autophagy cytoplasmic
LC3-I is processed to the autophagosomal membrane-bound
LC3-II form. In two NSCLC cell lines (H460 and H1975); we
observed signiﬁcant processing of LC3-I to LC3-II relative to
untreated controls (Figure 3c). LC3 processing was indepen-
dent of BAX and BAK as evidenced from H460
shBAX/BAK cells
and BAX/BAKDKO MEFs in which processing occurred to an
equivalent extent as that observed in their respective controls
(Figure 3d). Also, p70-S6 kinase was de-phosphorylated
following obatoclax treatment in H460 and H1975 cells
(Figure 3e).
Autophagy is associated with characteristic autophagolyso-
some formation best observed using electron microscopy.
Compared with untreated controls (Figure 4a), obatoclax
induced a profound cytoplasmic vacuolation in H1975 cells
visiblebytransmissionelectronmicroscopy(Figure4b).These
vacuoles were mainly devoid of obvious content, although a
fewexhibitedsomeelectron-densematerialwithintheirlumina.
At higher magniﬁcation, the peripheral cytoplasm revealed
vesicles containing phagocytosed organelles, free ribosomes
and endoplasmic reticulum (Figure 4c). Mitochondria were
found to form part of the autophagocytosed pay-load within
vesicles (Figures 4d and e). Profound cytoplasmic vacuolation
similartothatseeninH1975NSCLCcellsalongwithsigniﬁcant
LC3 processing was also observed in small-cell lung cancer
cell lines following obatoclax treatment (data not shown).
Figure4 ObatoclaxinducesdramaticultrastructuralvacuolationinH1975NSCLCcells.(a)H1975-untreatedcontrolcells.Untreatedcellswereprocessedbythestandard
protocol adopted for all other samples.The cytoplasmappears normal and is typiﬁed by the presence of numerous mitochondria (arrows), cisternae of endoplasmic reticulum
(*) and an extensive array of superﬁcial lamellae (L). The nucleus exhibits scattered arrays of condensedheterochromatin, frequent nuclear pores and a prominent nucleolus.
(b) Following 48h treatment with 500nM, obatoclax seems to induce a profound vesiculation of the cytoplasm. Many of these membrane vesicles are devoid of obvious
content, although a few exhibit some electron dense material within their lumina (arrows). At this stage the nuclei do not appear to have suffered any change. (c) Higher
magniﬁcationofperipheralcytoplasmrevealsthatvesiclecontentisofmixedorigincomprisingphagocytosedorganelles,freeribosomesandendoplasmicreticulum.(dande)
Mitochondria form part of the autophagocytosed pay-load within vesicles, although none have been found to undergo any signiﬁcant change to their inner membranes
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Cell Death and DiseaseObatoclax-induced LC3 processing is independent of
beclin-1. Beclin-1 (human ortholog of yeast Atg-6) is a key
apical regulator of autophagy. It is constitutively bound by
pro-survival BCL-2 family proteins BCL-xl, BCL-2 and MCL-1.
We therefore examined the role of beclin-1 with respect to
LC3 processing following obatoclax treatment. H460 NSCLC
cells stably expressing short hairpin RNAs targeting BECN1
(H460
BECN) were established and three clones selected
(H460
shBECN 3E, H460
shBECN 3F and H460
shBECN 4E) displaying
between 60–90% knockdown (Figure 5a). Stable knockdown
of beclin-1 did not alter the sensitivity of H460 cells to
obatoclax as assessed by ViaLight viability assay (data not
shown). Consistent with loss of beclin-1, each clone
exhibited a reduction in hVps34-speciﬁc activity, indicating
a functional defect in hVps34 signaling, both basally and
following acute nutrient deprivation (Figure 5b). Loss of
beclin-1 expression did not signiﬁcantly alter obatoclax-
induced LC3 processing in any of the clones (Figure 5c),
and was conﬁrmed using transient siRNA silencing
(Figure 5d). Consistent with these ﬁndings, neither
3-methyladenine nor wortmannin were capable of inhibiting
LC3 processing following obatoclax treatment (data not
shown). Furthermore, obatoclax treatment in H1975 and
H460 NSCLC cells caused a signiﬁcant reduction in beclin-1
expression (Figure 5e).
Obatoclax-induced LC3 processing requires Atg7. To
establish whether autophagy machinery was required at all
for LC3 processing following obatoclax treatment, we next
assessed whether there was a requirement for Atg7 using
H460
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Figure 5 Obatoclax-induced autophagy is independent of beclin-1. (a) H460 NSCLC cells were stably transfected with shRNA targeting beclin-1 (H460
shBECN). Three
stablecloneswereselected(3E,3F,and4E)displayingsigniﬁcantknockdowninthelevelofbeclin-1asassessedbySDS–PAGE(samplesruninduplicate),relativetocontrol
cells stably transfected with a non-targeting shRNA (H460
shNT). a-Tubublin was used a loading control. (b) hVps34 activity is reduced in H460
shBECN cells. hVps34-speciﬁc
lipid kinase activity was determined in each H460
shBECN clone. Cells were cultured to 80–90% conﬂuency then washed three times in PBS before depriving them of amino
acids for 0 and 2h in EBSS. hVps34 activity was expressed as speciﬁc activity after normalizing to the amount of immunoprecipitated hVps34 detected by immunoblotting.
Data are expressed as mean±S.D. (c) Stable knockdown of beclin-1 fails to inhibit obatoclax-induced LC3 processing. H460
shBECN and H460
shNT cells were treated with
indicateddoses of obatoclax for 48h and the level of LC3 processing in each clone relative to H460
shNT cells was determined by SDS–PAGE. GAPDH was used as a loading
control. (d) Transient knockdownof beclin-1 fails to inhibit obatoclax-induced LC3 processing. H460 NSCLCcells were transfected with 100nM of siRNA targeting beclin-1 or
control non-targeting (NT) siRNA for 48h. NT- and beclin-1-transfected cells were then treated with 500nM obatoclax for 48h. The level of LC3 processing and PARP
cleavagewasdeterminedbySDS–PAGE.Thelevelofbeclin-1knockdownwasalsodeterminedbySDS–PAGE.a-Tubulinwasusedasaloadingcontrol.(e)Levelsofbeclin-
1 decrease signiﬁcantly following obatoclax treatment. H460 and H1975 cells were treated with 500nM obatoclax for 48h and the levels of beclin-1 determined by SDS–
PAGE. a-Tubulin was used as a loading control. The level of beclin-1 decrease was quantiﬁed by densitometry analysis using ImageJ. Data represent mean±S.D.
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Cell Death and DiseaseRNA interference. Atg7 plays a pivotal role in the formation of
autophagosomes. When expression of Atg7 was silenced
using siRNA, LC3 processing was reduced in both H460 and
H1975 cells. siRNA knockdown of Atg5 also attenuated LC3
processing (Figure 6a). To deﬁnitively conﬁrm a requirement
for Atg7, we examined the levels of LC3 processing and
cytoplasmic vacuolation in Atg7
 /  MEFs; LC3 processing
(Figure 6b) and cytoplasmic vacuolation (data not shown)
were completely abolished following obatoclax treatment.
However, induction of apoptosis assessed by PARP
cleavage was not affected by loss of Atg7 (Figures 6a and b),
however, siRNA knockdown of Atg5 in H460 cells altered the
pattern of PARP cleavage; there was a reduction in full-
length PARP but no cleaved 89kDa product detectable
(Figure 6a).
Autophagy is not essential for obatoclax-induced
toxicity. To assess whether autophagy was a requirement
for obatoclax-induced toxicity, we examined the effect of Atg7
knockout on viability and long-term clonogenicity of Atg7
 / 
MEFs treated with obatoclax. Obatoclax reduced the viability
of Atg7
 /  MEFs and WT MEFs equally, with no signiﬁcant
difference in their relative EC50 (Figure 6c). Loss of
clonogenicity was observed in Atg7
 /  MEFs with no
difference relative to their WT controls (Figure 6d), while the
long-term growth kinetics of Atg7
 /  MEFs was not
signiﬁcantly different from their WT controls following
obatoclax treatment (Figure 6e). siRNA silencing of Atg7 in
Bax/Bak DKO MEFs did signiﬁcantly rescue cells treated with
obatoclax, however, this rescue was not total (Figure 6f).
siRNA knockdown of Atg7 in BAX/BAK DKO MEFs
completely abolished LC3 processing (data not shown).
Obatoclax resistance is associated with a block in
apoptosis and a reduction in autophagy. To establish
whether cells that are resistant to obatoclax suppress
autophagy as well as apoptosis, we screened a panel of
cell lines for obatoclax resistance and identiﬁed H727
NSCLC cells with log-fold resistance to obatoclax
compared with H1975 and H460 NSCLC cells (Figure 7a).
H727 cells also displayed signiﬁcant differences in their
clonogenic survival in response to obatoclax (Figure 7b) and
failed to undergo caspase 3, caspase 9 or PARP cleavage
(Figure 7c). We wanted to examine the kinetics of apoptosis
and autophagy induction to further try and delineate their
relationship. In both H1975 and H727 NSCLC cells, LC3
processing was observed as early as 6h following obatoclax
treatment, which increased and was sustained through to
48h in both cell lines. PARP cleavage however, was only
observed in sensitive H1975 cells, and only signiﬁcantly at
48h, whereas no PARP cleavage was observed in H727
cells (Figure 7d), even up to 72 and 96h post drug exposure
(data not shown). When examined by TEM, H727 cells also
exhibited cytoplasmic vacuolation post obatoclax exposure
(data not shown). Similar to H1975 and H460 cells, H727
NSCLC cells also underwent de-phosphorylation of S6
kinase following obatoclax treatment (data not shown).
To further determine the role of apoptosis and autophagy
in mediating resistance to obatoclax, we selected H460
NSCLC cells for obatoclax resistance using ENU to induce
mutagenesis. H460 obatoclax-resistant cells (H460-ENU)
displayed a signiﬁcantly higher EC50 for viability at 48h, and
greater clonogenic survival relative to parental H460s
(H460par) (Figure 8a). In common with H727 cells, PARP
and caspase 9 cleavage were both blocked in H460-ENU
cells, and this was associated with absence of obatoclax-
induced SMAC and cytochrome c release (Figures 8b and c).
Processing of LC3 following obatoclax treatment was also
observed in H460-ENU cells; however, this was to a lesser
extent than in H460par cells (Figure 8b). Proﬁling of BCL-2
family expression was conducted to establish if acquired
resistance to obatoclax was associated with alterations in
BCL-2 family expression, however, no signiﬁcant differences
were observed at either the whole-cell or mitochondrial level
(data not shown).
Discussion
Obatoclax is one of several pro-survival BCL-2 family protein
inhibitors to have emerged in recent years and is currently in
clinical development in both solid tumors and hematopoietic
malignancies. In this study, we investigated the pharmaco-
dynamics of obatoclax. We found that in NSCLC cells, obatoclax
inducedbothon-targetdissociationofMCL-1-BAKcomplexes
and initiation of apoptosis associated with mitochondrial BAK
conformation change and release of cytochrome c and
SMAC. A requirement of BAX and BAK for obatoclax-induced
apoptosis has been shown in other models previously.
Nguyen et al. (2007) found that in baby kidney epithelial cells
from mice deﬁcient for BAX and BAK obatoclax failed to
induce apoptosis,
18 whereas Mott et al. (2008) showed that
DKO MEFs were resistant to obatoclax-induced cell death as
assessed by clonogenic assay.
20 However, Vogler et al.
(2009) investigating cell death induced by obatoclax (as well
as other pro-survival BCL-2 family inhibitors) suggested that
obatoclax caused cell killing completely independently of BAX
and BAK, and did not activate the intrinsic apoptosis pathway,
but rather acted as a mitochondrial poison that induced
features that could be mistaken as apoptosis.
24 However, we
have shown here that apoptosis as assessed by caspase and
PARP cleavage (speciﬁc markers of apoptosis) induced by
obatoclax is dependent on BAX and BAK. Furthermore, the
conclusion reached by Vogler et al.
24 that obatoclax acts as a
mitochondrial poison was reached from the results of
experiments using 10mM doses of obatoclax, a dose that is
up to two log-folds higher than what we have used in results
presented here, and signiﬁcantly higher than clinically
relevantdoses.Dosesuseddifferaccordingtotrialschedules;
however, the approximate peak plasma concentration is
100ng/ml (B250mM).
We have shown that despite the evidence that obatoclax
induces BAX/BAK-dependent apoptosis, this is not sufﬁcient
to account for toxicity and loss of clonogenic survival, as
evidenced by sensitivity of BAX and BAK DKO MEFs, and cell
lines stably expressing shRNAs for BAX and BAK. Obatoclax
mediates loss of clonogenic survival in association with a
marked reduction in growth kinetics and reduction in cellular
ATP level without loss of plasma membrane integrity.
This suggested that obatoclax could be inducing loss of
viabilitybyamechanismdistinctfromapoptosisandprompted
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Figure 6 Obatoclax-induced LC3 processingrequires Atg7 and Atg5. (a) siRNA knockdown of Atg5/7reduces obatoclax-induced LC3 processing. H460 (top) and H1975
(bottom)cellsweretransfectedwith100nMofAtg7orAtg5siRNA,orcontrolnon-targetingsiRNA(NT)for48h,andthentreatedwith500nMobatoclaxforafurther48h.The
levelof LC3processingandPARPcleavagein Atg5/7-transfectedcellsrelativeto NT-transfected cellswas then determined by SDS–PAGE. a-Tubulinandb-actinwere used
as loading controls. (b) Obatoclax-induced LC3 processing is lost in mouse embryonic ﬁbroblasts derived from mice deﬁcient for Atg7. Wild-type and Atg7
 /  MEFs were
treated with 500nM obatoclax for 48h and the level of LC3 processing and PARP cleavage was determined by SDS–PAGE. b-Actin was used as a loading control.
(c) Autophagy is not essential for obatoclax-induced toxicity. The effect on the viability of Atg7
 /  MEFs and their wild-type controls following obatoclax treatment for 48h.
EC50valuesforeachcelllinewere;Atg7WT84nM;Atg7
 / 58nM.Dataarepresentedasmean±S.D.(d)LossofAtg7failstorescuecells.Atg7wild-typeandAtg7
 / cells
were plated in 24-well plates at single-cell densities and treated with indicated doses of obatoclax for 24h. Media was replaced after 24h and cells allowed to form colonies
over 7–10 days to assess the effect of obatoclax on clonogenic growth. Data are presented mean±S.E. (e) Loss of Atg7 fails to rescue cells over the long term. Cells were
seeded in 6-well plates and drugged at indicted doses. Cells were then monitored using the INCUCYTE live cell imaging system (Essen BioScience). Cell conﬂuency was
determined using calculations derived from phase-contrast images. This data was condensed using algorithms into quantiﬁed metrics to obtain kinetic proliferation curves. (f)
siRNA knockdown of Atg7 rescues BAX/BAK DKO MEFs. DKO MEFs were transfected with 100nM of Atg7 siRNA or control non-targeting siRNA (NT) for 48h. Cells were
then treated with indicated doses of obatoclax for a further 48h and the effect on viability determined by ViaLight assay. Data are presented as mean±S.D. The level of
knockdown was determined by SDS–PAGE. GAPDH was used as a loading control
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Cell Death and Diseaseustoexaminetheroleoftheautophagymachinery.Obatoclax
has been shown to induce autophagy in several reports.
24–28
In contrast to all earlier studies, this is the ﬁrst report to show
a beclin-1-independent mechanism of obatoclax-induced
autophagy.
Beclin-1 is an initiator of autophagy that contains a BH3
domainandisrestrainedbypro-survivalBCL-2familyproteins
BCL-2, BCL-xl, BCL-w and MCL-1.
29–31 However, only
endoplasmic reticulum-targeted BCL-2/xl can inhibit auto-
phagy induced by beclin-1.
30 Inhibition of pro-survival BCL-2
family proteins releases beclin-1, which binds and activates
Vps34 lipid kinase and induces formation of the phago-
phore.
32 Beclin-1 has also been shown to be a haplo-
insufﬁcient tumor suppressor,
33,34 and it has been suggested
that displacement of beclin-1 from its BCL-2 binding partners
may be a means to induce a toxic form of autophagy in cancer
cells,
35knownastypeIIprogrammedcelldeath.Furthermore,
it has been shown that in the absence of BAX and BAK,
induction of autophagy was used as a default cell death
mechanism.
36 Accordingly, we explored the activation of
autophagy by obatoclax, the requirement for components of
the autophagy machinery and the implications for cell fate.
Using stable and transient knockdown of beclin-1, we
showed that the biochemical hallmark of autophagy, LC3
processing, occurs irrespective of beclin-1 expression, but is
entirely dependent upon the expression of Atg7. Induction of
apoptosis as assessed by PARP cleavage was unaffected by
loss of Atg7 (or Atg5), however, loss of Atg5 in H460 cells did
alter the pattern of PARP cleavage (see Figure 6a); there was
a reduction in full-length PARP but no appearance of a
cleaved 89kDa fragment indicative of apoptosis. During
necrosis PARP can be cleaved to a 50kDa fragment by
lysosomalproteases,
37however,thisisunlikelytobethecase
in regards to obatoclax. As shown in Figure 3a, obatoclax
failed to induce a loss of plasma membrane integrity, which
would not be the case if necrosis was being induced. The
mechanism underlying Atg7-dependent, beclin-1-indepen-
dent autophagy by obatoclax is unclear. Another pro-survival
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Figure 7 H727 NSCLC cells are resistant to obatoclax-induced apoptosis yet still undergo autophagy. (a) H727 NSCLC cells are resistant to obatoclax. H727 and H1975
NSCLC cells were treated with obatoclax at the indicated doses for 48 (left) or 72h (right), and the viability of cells determined by ViaLight assay. The EC50 values of cells at
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24h. Media was replaced after 24h and cells allowed to form colonies over 7–10 days to assess the effect of obatoclax on clonogenic growth. Data are presented as
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Cell Death and DiseaseBCL-2 antagonist, gossypol, has very recently been shown to
induce both beclin-1-dependent and -independent autop-
hagy;
38 in MCF-7 cells, gossypol-induced autophagy was
beclin-1-dependent, whereas in HeLa cells it was beclin-
1-independent. Regardless of the cell line, gossypol-induced
autophagy was found to be cytoprotective. In neuroblastoma
cells, the neurotoxin 1-methyl-4-phenylpyridinium (MPP
þ), a
mitochondrial complex 1 inhibitor, was found to induce
mitochondrial injury and beclin-1-independent Atg5/7-depen-
dent mitophagy.
39 Whether obatoclax is acting in a similar
manner is unknown at present.
Obatoclax induced dramatic ultra-structural changes that
appeared to be dependent upon Atg7; morphologically, the
patternofvacuolationwas nottypical forautophagy,however,
within this background of inclusion bodies there was evidence
of mitochondrial engulfment and autophagosome formation.
We propose that these ultra-structural changes most likely
reﬂect a direct effect of obatoclax that is independent of both
the apoptosis and autophagy machinery, but could contribute
to cell fate. Cells with either de novo log-fold resistance to
obatoclax, or selected for resistance to obatoclax, exhibited
marked suppression of apoptosis. ENU-selected H460 cells
(H460-ENU) did not exhibit signiﬁcant alterations in their
BCL-2 family expression. This is the ﬁrst study to examine the
phenotype of isogenic cells selected for obatoclax resistance.
However, apoptosis was suppressed by an unknown
mechanism not involving loss of BAX and/or BAK expression.
Acquisition of apoptosis block suggests that this process is
important in determining cell fate, and is supported by the
ﬁnding that, although BAX/BAK silencing in H460 cells did not
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Cell Death and Diseaseabolish the loss of clonogenic survival associated with
obatoclax, it reduced apoptosis sensitivity signiﬁcantly.
Similarly, in H727 cells, resistance was associated with a
block in apoptosis. With respect to autophagy, resistant cells
reduced but did not abolish LC3 processing. H727 cells also
displayed cytoplasmic vacuolation following obatoclax treat-
ment; however, this was not as extensive or dramatic as
observed in H1975 cells. The question of whether H460-ENU
cells exhibit cytoplasmic vacuolation in response to obatoclax
treatment is currently being addressed. To establish whether
cell death occurred through redundant pathways involving
apoptosis or autophagy, silencing of Atg7 in BAX/BAK DKO
MEFswasconducted.Despitepartialrescuebyknockdownof
Atg7, obatoclax still exhibited toxicity irrespective of loss of
these two pathways. We conclude that cell death, and
importantly the mechanisms underlying resistance are likely
to involve the alteration of genes outside of either the
autophagy or apoptosis pathways.
Materials and Methods
Reagents. Obatoclax mesylate (GX15-070) was provided by GeminX
Pharmaceuticals (Montreal, Canada). Obatoclax powder was dissolved in DMSO
to a concentration of 5mM, aliquoted and stored at  201C. Recombinant human
TRAIL was purchased from Calbiochem (San Diego, CA, USA). TRAIL was
dissolved in sterile PBS/BSA 0.1% to a concentration of 20mg/ml, aliquoted
and stored at  801C. ENU was purchased from Sigma-Aldrich (St. Louis, MO,
USA) and dissolved in DMSO to a concentration of 50mg/ml, aliquoted and stored
at  801C.
Cell lines and culture. All cells were maintained in 5% CO2 at 371C. H1975
and H460 non-small-cell lung cancer (NSCLC) cells were maintained in Roswell
Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine
serum and 50mg/ml penicillin/streptomycin (all supplied by Life Technologies Inc.,
Paisley, Scotland). H460
shBAX/BAK and H460
shNT/NT cells were maintained in RPMI
as described above, supplemented with 2mg/ml puromycin and 400mg/ml G418
(both from Sigma-Aldrich). H727 NSCLC cells were maintained in Dulbecco’s
Modiﬁed Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 1mM
sodium pyruvate and 50mg/ml penicillin/streptomycin (all supplied by Life
Technology Inc.). BAX/BAK double-knockout mouse embryonic ﬁbroblasts (DKO
MEFs) and their WT controls were a kind gift from Dr. Scott Oakes (University of
California, San Francisco, CA, USA). WT and DKO MEFs were maintained in
Iscove’s Modiﬁed Dulbecco’s Medium (IMDM) supplemented with 10% fetal bovine
serum, 2mM L-glutamine, 0.1mM non-essential amino acids and 50mg/ml
penicillin/streptomycin (all from Life Technology Inc.). Atg7 WT and Atg7
 /  MEFs
were a kind gift from Dr. Masaaki Komatsu (The Tokyo Metropolitan Institute
Medical Science, Tokyo, Japan). Atg7 WT and Atg7
 /  MEFs were maintained in
DMEMsupplemented with 10% fetal bovine serum, 1mM sodium pyruvate,0.1mM
non-essential amino acids and 50mg/ml penicillin/streptomycin (all from Life
Technology Inc.)
Immunoblot analysis. When analyzing phosphoproteins, cells were scraped
into ice-cold PBS supplemented with 1mM Na3VO4, otherwise cells were scraped
into media and pelleted by centrifugation at 1500r.c.f at 41C for 5min. Whole-cell
lysates were obtained by snap freezing cells in RIPA lysis buffer (50mM Tris
(pH7.4),150mMNaCl,5mMEDTA,1%TritonX,0.1%SDSandoneminicomplete
protease inhibitor tablet per 10ml (Roche Diagnostics, Indianapolis, IN, USA)) and
defrosting frozen lysates on ice. When analysing phosphoproteins, RIPA was
further supplemented with 1mM Na3VO4 and 1mM NaF. Insoluble cell debris was
removed from cell lysates by centrifugation at 13000r.p.m for 15min at 41C.
Samples were resolved by SDS–PAGE on 12% gels, transferred to nitrocellulose
membranes and immunoblotted with the indicated primary antibodies. Goat anti-
rabbit and goat anti-mouse horseradish peroxidise-conjugated secondary
antibodies (Dako UK Ltd., Cambridgeshire, UK) were used in conjunction with
appropriate primary antibodies. Bound antibodies were visualized using Amersham
ECL plus chemiluminescent reagents (GE Healthcare Life Sciences,
Buckinghamshire, UK) and Fuji-RX X-ray ﬁlm (Fuji, Bedfordshire, UK). Rabbit
primary antibodies used were those raised against cleaved caspase 9, cleaved
caspase 3, LC3B, beclin-1, Atg5, Atg7, BAX, BAK and phospho S6 kinase (thr389)
(all from Cell Signaling Technology Inc., Danvers, MA, USA), BAK N-terminus
(Millipore,Billerica,MA,USA)anda-tubulin(Abcam,Cambridge,MA,USA). Mouse
primary antibodies used were those raised against PARP (eBiosciences, San
Diego, CA,USA), SMACandCytochromec (bothCalbiochem),GAPDHand VDAC
(both Abcam), and b-actin (Sigma-Aldrich).
Immunoprecipitation. H460 cells were treated with obatoclax for 6, 24 and
48h. The cells were then harvested, washed in ice-cold PBS and lysed with NP-40
whole-cell lysis buffer (150mM NaCl, 50mM TrisHcl pH8, 5mM EDTA pH8,
1% NP40, 2mM DTT, 1mM PMSF, 1mg/ml pepstatin A, 1mg/ml aprotinin, 2mg/ml
leupeptin and 1mM Benzamidine). Immunoprecipitation assays were carried out
using 500mg of protein and either 1mg of murine a-BAK antibody (BD Biosciences,
Franklin Lakes, NJ, USA) or a murine IgG isotype control antibody (Dako, Glostrup,
Denmark). Lysates were incubated at 41C overnight with 20ml packed volume
protein-G agarose beads (Sigma-Aldrich). Beads and bound immuno-complexes
were spundownat low speed andthesupernatantremovedandthenwashedthree
times with 0.5ml IP wash buffer (20mM Hepes pH7.9, 75mM KCL or 150mM KCl,
2.5mM MgCl2, 0.1% NP-40, 1mM DTT, 1mM PMSF, 1mg/ml pepstatin A, 1mg/ml
aprotinin, 2mg/ml leupeptin and 1mM Benzamidine). Immunoprecipitated proteins
wereelutedwith30mlofSDSsamplebufferandheatedat951Cfor5min.Avolume
of 15ml of the eluted samples was separated by SDS–PAGE and immunoblotted
with a-MCL-1 antibody (Cell Signaling Technology Inc.).
Densitometry analysis. Densitometry analysis of western blots was carried
out using ImageJ public domain image processing and analysis software.
ATP luminescent viabilityassay. The viability of cells on the basis of ATP
levelswasdeterminedusingViaLightpluscellproliferationandcytotoxicitybioassay
kit(LonzaGroupLtd.,Basel,Switzerland).Analysiswascarriedoutaccordingtothe
manufacturer’s instructions.
Adenylate kinase luminescent cytotoxicity assay. The level of
adenylate kinase release from cells was used as a measure of cytotoxicity.
Adenylate kinase release was measured using ToxiLight non-destructive
cytotoxicity bioassay kit (Lonza Group Ltd., Basel, Switzerland). Analysis was
carried out according to the manufacturer’s instructions.
Cell proliferation kinetics. Cells were seeded in 6-well plates and drugged
at indicted doses. Cells were then monitored using the INCUCYTE live cell imaging
system (Essen BioScience, Ann Arbor, MI, USA). The INCUCYTE live cell imaging
systemwasplacedinacellcultureincubatoroperatedat371Cand5%CO2.Images
wereacquiredevery3h fora periodof7days.A totalof 16 user-deﬁneddatapoints
were used to calculate cell conﬂuency over each well in a 6-well plate. Cell
conﬂuency was determined using calculations derived from phase-contrast images.
This data was condensed using algorithms into quantiﬁed metrics to obtain kinetic
proliferation curves.
Clonogenic assays. Cells were plated into 24-well plates at single-cell
density, followed by treatment with indicated doses of obatoclax for 24h. Medium
was then replaced and cells were allowed to grow until untreated control wells had
formed sufﬁcient colonies.
Isolation of mitochondrial and cytosolic fractions. Following
speciﬁed treatment periods harvested cells were incubated on ice for 15min,
centrifugedat1500r.c.f 5minat41Candwashedinmitochondrialisolationbuffer
(MIB) (200mM Mannitol, 70mM Sucrose, 1mM EGTA, 10mM HEPES, 0.5mg/ml
BSA,andpH7.4).CellswereresuspendedinMIBandhomogenizedusingadounce
homogenizer. The resulting homogenate was centrifuged at 800r.c.f 5min at
41C. Supernatants were removed and centrifuged at 10000r.c.f 10min at 41C.
The resulting pellet was the mitochondrial fraction and supernatant used as the
cytosolic fraction.
Determination of BAK conformation by proteolysis. Isolated
mitochondria were resuspended in mitochondrial respiration buffer (MRB)
(125mM KCl, 5mM HEPES, 1mM EGTA, 1mM KHPO4, 2.5mM MgCl2, 0.4%
BSA, 7mM Succinate, and pH 7.4) and incubated with 125mg/ml trypsin (GIBCO,
Invitrogen, Carlsbad, CA, USA) on ice for 20min. Trypsin digestion was
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Rutherford, NJ, USA) and mitochondria pelleted by centrifugation at
10000r.c.f 10min at 41C and lysed in RIPA buffer.
siRNA transfections. Pre-designed siRNAs were purchased for beclin-1,
Atg5 and Atg7 (Qiagen, Germantown, MD, USA). As control siRNA,
ON-TARGETplus non-targeting pool was purchased from Dharmacon (Lafayette,
CO, USA). siRNA transfections were performed using DharmaFect 1 transfection
reagent (Dharmacon) according to the manufacturer’s instructions.
shRNAtransfectionsandcreationofstablecelllines. Pre-designed
shRNA plasmids targeting BAX, BAK and BECLN1 were purchased from SA
Biosciences (Frederick, MD, USA). H460 NSCLC cells were stably transfected with
each of four different sequences using FuGene 6 transfection reagent (Roche
Diagnostics). Transfected cells were put through two rounds of selection using
appropriate antibiotic (puromycin 2mg/ml, G418 400mg/ml) to select multiple stable
clones.Clonesjudged to havebest knockdownweretakenforward for analysis.For
double transfection of BAX and BAK, cells stably expressing shRNA-targeting BAX
were re-transfected with shRNA-targeting BAK and clones expressing stable
knockdown of both BAX and BAK were selected.
hVps34-speciﬁc activity. Cells were cultured to 80–90% conﬂuency then
washed three times in PBS before depriving them of amino acids for 0 and 2h in
Earle’s Balanced Salt Solution (EBSS) (Life Technology Inc.). Following lysis, cell
extracts were clariﬁed by centrifugation and then subjected to immunoprecipitation
with anti-hVps34 antibody. Immunocomplexes were assayed for hVps34 lipid-
kinase activity with PtdIns substrate and Mn2þ-(
32P-g-ATP). Lipid products were
visualized by exposure of TLC plates to a phosphor screen, read using a Fuji FLA-
7000 and quantied using multi-gauge software. Duplicate immunoprecipitations
were resolved by SDS–PAGE and immunoblotted for hVps34 and beclin-1. hVps34
activity was expressed as speciﬁc activity after normalizing to the amount of
immunoprecipitated hVps34 detected by immunoblotting.
Transmission electron microscopy. Following treatment with obatoclax,
cells were trypsinized and ﬁxed in TEM ﬁxative (4% paraformaldehyde, 2.5%
glutaraldehyde made up in 0.1M sodium cacodylate buffer). Fixation was for 4h at
371C after which excess ﬁxative was washed out in cacodylate buffer (4–6h)
before samples were post-ﬁxed (1h) in 1% aq osmium tetroxide then dehydrated in
graded ethanol solutions before embedment in SPI-PON 812 epoxy resin (SPI
chemicals Ltd., West Chester, PA, USA).
Selection of obatoclax-resistant cells. Cells resistant to obatoclax were
selected using ENU to induce mutagenesis. H460 NSCLC cells were seeded into
T80tissuecultureﬂasks(Nunc,LifeTechnologiesInc.)at50–60%conﬂuency.Cells
were then exposed to 75mg/ml ENU (Sigma-Aldrich) for 24h. Following ENU
exposure, cells were washed three times with RPMI and re-seeded in complete
growth medium and allowed to proliferate for 1 week. After 1 week, cells were
seeded into 96-well plates at 8000 cells per well and treated with a range of
obatoclax doses. The concentrations of obatoclax used were 0.3, 1, 3, and 10mM.
Wells were observed for growth by visual inspection for 4–8weeks. When growth
occurred cells were transferred to 24-well plates and expanded in the presence of
the corresponding dose of obatoclax.
Statistical analysis. All data represent at least three independent
experiments and are expressed as mean±S.D. or mean±S.E. as stated.
Differences between groups were compared using Student’s t-test where
appropriate (*P-value ¼0.01–0.05, **P-value¼0.001–0.01, ***P-value¼
o0.001). EC50 values were determined using non-linear regression on GraphPad
Prism 5 (GraphPad, La Jolla, CA, USA).
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